Piper Sandler analyst Christopher Raymond downgraded Deciphera to Neutral from Overweight with a price target of $25.60, up from $23, after the company entered a definitive merger agreement under which ONO Pharmaceutical will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential